Portnoy Law Firm Announces Class Action on Behalf of Hims & Hers Health, Inc. Investors

By GlobeNewswire

LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc., (“Hims & Hers” or the "Company") (NYSE: HIMS) investors of a class action on behalf of investors that bought securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). Hims & Hers investors have until November 2, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/hims-hers-health-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Hims & Hers shared consumers’ health information with third-party advertising platforms; (ii) Hims & Hers charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is “right for them”; (iii) the foregoing conduct subjected Hims & Hers to regulatory scrutiny; (iv) as a result of the foregoing, Hims & Hers was reasonably likely to incur fees and penalties; and (v) as a result of the foregoing, defendants’ positive statements about Hims & Hers’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, the Federal Trade Commission allegedly announced it had filed a lawsuit against Hims & Hers “alleging that the telehealth provider shared consumers’ sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers’ privacy and deceives users about its billing and cancellation practices.”  The Hims & Hers class action lawsuit further alleges that, according to the Federal Trade Commission’s complaint, Hims & Hers engages in other deceptive advertising practices, including failing to “clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is ‘right for them.’”  Additionally, the Hims & Hers class action lawsuit alleges that the Federal Trade Commission’s complaint includes allegations that Hims and Hers “shared consumers’ sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. (‘Meta’) and Snap Inc. (‘Snap’).”  On this news, the price of Hims and Hers shares declined nearly 15%, according to the complaint.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.